Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study findings from Tokyo Medical University, Department of Otolaryngology broaden understanding of cancer gene therapy
May 13th, 2008
New investigation results, 'Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis,' are detailed in a study published in Oncology Reports. "The fragile histidine triad (FHIT), frequently lost in many cancers, was identified as a candidate tumor suppressor gene at chromosome 3p locus 14.2. Loss of the FHIT protein because of the alteration or loss of heterozygosity by genetic deletion occurs in a variety of epithelial tumors including head and neck cancer," investigators in Tokyo, Japan report. "However, the biological function of the FHIT protein is still unknown and its role in intrinsic...
Source: Cancer Weekly (2008-05-13)
|
